Christina Yoon1, Fred C Semitala2,3, Lucy Asege4, Jane Katende3, Sandra Mwebe4, Alfred O Andama2,4, Elly Atuhumuza4, Martha Nakaye4, Derek T Armstrong5, David W Dowdy6, Charles E McCulloch7, Moses Kamya2,3,4, Adithya Cattamanchi1,8. 1. 1 Division of Pulmonary & Critical Care Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, and. 2. 2 Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. 3. 3 Makerere University Joint AIDS Program, Kampala, Uganda. 4. 4 Makerere University-University of California, San Francisco Research Collaboration, Kampala, Uganda. 5. 5 Johns Hopkins University, School of Medicine, Baltimore, Maryland. 6. 6 Division of Infectious Disease Epidemiology, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and. 7. 7 Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. 8. 8 Curry International Tuberculosis Center, University of California, San Francisco, Oakland, California.
Abstract
RATIONALE: The recommended tuberculosis (TB) intensified case finding (ICF) algorithm for people living with HIV (symptom-based screening followed by Xpert MTB/RIF [Xpert] testing) is insufficiently sensitive and results in unnecessary Xpert testing. OBJECTIVES: To evaluate whether novel ICF algorithms combining C-reactive protein (CRP)-based screening with urine Determine TB-LAM (TB-LAM), sputum Xpert, and/or sputum culture could improve ICF yield and efficiency. METHODS: We compared the yield and efficiency of novel ICF algorithms inclusive of point-of-care CRP-based TB screening and confirmatory testing with urine TB-LAM (if CD4 count ≤100 cells/μl), sputum Xpert, and/or a single sputum culture among consecutive people living with HIV with CD4 counts less than or equal to 350 cells/μl initiating antiretroviral therapy in Uganda. MEASUREMENTS AND MAIN RESULTS: Of 1,245 people living with HIV, 203 (16%) had culture-confirmed TB including 101 (49%) patients with CD4 counts less than or equal to 100 cells/μl. Compared with the current ICF algorithm, point-of-care CRP-based TB screening followed by Xpert testing had similar yield (56% [95% confidence interval, 49-63] vs. 59% [95% confidence interval, 51-65]) but consumed less than half as many Xpert assays per TB case detected (9 vs. 4). Addition of TB-LAM did not significantly increase diagnostic yield relative to the current ICF algorithm but provided same-day diagnosis for 26% of TB patients with advanced HIV. Addition of a single culture to TB-LAM and Xpert substantially improved ICF yield, identifying 78% of all TB cases. CONCLUSIONS: Point-of-care CRP-based screening can improve ICF efficiency among people living with HIV. Addition of TB-LAM and a single culture to Xpert confirmatory testing could enable HIV programs to increase the speed of TB diagnosis and ICF yield.
RATIONALE: The recommended tuberculosis (TB) intensified case finding (ICF) algorithm for people living with HIV (symptom-based screening followed by Xpert MTB/RIF [Xpert] testing) is insufficiently sensitive and results in unnecessary Xpert testing. OBJECTIVES: To evaluate whether novel ICF algorithms combining C-reactive protein (CRP)-based screening with urine Determine TB-LAM (TB-LAM), sputum Xpert, and/or sputum culture could improve ICF yield and efficiency. METHODS: We compared the yield and efficiency of novel ICF algorithms inclusive of point-of-care CRP-based TB screening and confirmatory testing with urine TB-LAM (if CD4 count ≤100 cells/μl), sputum Xpert, and/or a single sputum culture among consecutive people living with HIV with CD4 counts less than or equal to 350 cells/μl initiating antiretroviral therapy in Uganda. MEASUREMENTS AND MAIN RESULTS: Of 1,245 people living with HIV, 203 (16%) had culture-confirmed TB including 101 (49%) patients with CD4 counts less than or equal to 100 cells/μl. Compared with the current ICF algorithm, point-of-care CRP-based TB screening followed by Xpert testing had similar yield (56% [95% confidence interval, 49-63] vs. 59% [95% confidence interval, 51-65]) but consumed less than half as many Xpert assays per TB case detected (9 vs. 4). Addition of TB-LAM did not significantly increase diagnostic yield relative to the current ICF algorithm but provided same-day diagnosis for 26% of TB patients with advanced HIV. Addition of a single culture to TB-LAM and Xpert substantially improved ICF yield, identifying 78% of all TB cases. CONCLUSIONS: Point-of-care CRP-based screening can improve ICF efficiency among people living with HIV. Addition of TB-LAM and a single culture to Xpert confirmatory testing could enable HIV programs to increase the speed of TB diagnosis and ICF yield.
Entities:
Keywords:
C-reactive protein; intensified case finding; screening; tuberculosis; urine lipoarabinomannan
Authors: Faiz Ahmad Khan; Sabine Verkuijl; Andrew Parrish; Fadzai Chikwava; Raphael Ntumy; Wafaa El-Sadr; Andrea A Howard Journal: AIDS Date: 2014-06-19 Impact factor: 4.177
Authors: Y Hanifa; K L Fielding; S Charalambous; E Variava; B Luke; G J Churchyard; A D Grant Journal: Int J Tuberc Lung Dis Date: 2012-07-12 Impact factor: 2.373
Authors: Jonny Peter; Grant Theron; Duncan Chanda; Petra Clowes; Andrea Rachow; Maia Lesosky; Michael Hoelscher; Peter Mwaba; Alex Pym; Keertan Dheda Journal: BMC Infect Dis Date: 2015-07-09 Impact factor: 3.090
Authors: Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet; Herbert Y Kressel; Nader Rifai; Robert M Golub; Douglas G Altman; Lotty Hooft; Daniël A Korevaar; Jérémie F Cohen Journal: BMJ Date: 2015-10-28
Authors: Stephen D Lawn; Andrew D Kerkhoff; Rosie Burton; Charlotte Schutz; Andrew Boulle; Monica Vogt; Ankur Gupta-Wright; Mark P Nicol; Graeme Meintjes Journal: BMC Med Date: 2017-03-21 Impact factor: 8.775
Authors: Helena Huerga; Gabriella Ferlazzo; Paolo Bevilacqua; Beatrice Kirubi; Elisa Ardizzoni; Stephen Wanjala; Joseph Sitienei; Maryline Bonnet Journal: PLoS One Date: 2017-01-26 Impact factor: 3.240
Authors: A Andama; D Jaganath; R Crowder; L Asege; M Nakaye; D Katumba; S Mwebe; F Semitala; W Worodria; M Joloba; S Mohanty; A Somoskovi; A Cattamanchi Journal: Diagn Microbiol Infect Dis Date: 2019-09-04 Impact factor: 2.803
Authors: Ruvandhi R Nathavitharana; Christina Yoon; Peter Macpherson; David W Dowdy; Adithya Cattamanchi; Akos Somoskovi; Tobias Broger; Tom H M Ottenhoff; Nimalan Arinaminpathy; Knut Lonnroth; Klaus Reither; Frank Cobelens; Christopher Gilpin; Claudia M Denkinger; Samuel G Schumacher Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226
Authors: Lelia H Chaisson; Fred C Semitala; Sandra Mwebe; Jane Katende; Lucy Asege; Martha Nakaye; Alfred O Andama; Elly Atuhumuza; Moses Kamya; Adithya Cattamanchi; Christina Yoon Journal: AIDS Date: 2022-06-22 Impact factor: 4.632
Authors: Devan Jaganath; Tania F Reza; Peter Wambi; Jascent Nakafeero; Emma Kiconco; Gertrude Nanyonga; Ernest A Oumo; Moses C Nsereko; Moorine P Sekadde; Mary G Nabukenya-Mudiope; Midori Kato-Maeda; Alfred Andama; Christina Yoon; Swomitra Mohanty; Eric Wobudeya; Adithya Cattamanchi Journal: J Pediatric Infect Dis Soc Date: 2022-07-21 Impact factor: 5.235
Authors: Lelia H Chaisson; Fred C Semitala; Lucy Asege; Sandra Mwebe; Jane Katende; Martha Nakaye; Alfred O Andama; Carina Marquez; Elly Atuhumuza; Moses Kamya; Adithya Cattamanchi; Christina Yoon Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne Journal: Cochrane Database Syst Rev Date: 2021-03-23
Authors: Sandra Z Mwebe; Christina Yoon; Lucy Asege; Martha Nakaye; Jane Katende; Alfred Andama; Adithya Cattamanchi; Fred C Semitala Journal: Diagn Microbiol Infect Dis Date: 2020-11-26 Impact factor: 2.803